US Food and Drug Administration Commissioner Robert Califf has emphasized the key public health paradox that in an era of unprecedented biomedical innovation, the country still faces an incredibly high chronic disease and early mortality burden.
Key Takeaways
-
A NASEM committee is researching whether drug development incentives and investments are aligned with unmet needs and disease burden.
“It is a conundrum,” Califf said during the 7 October meeting of the FDA’s Science Board. “We are leading the...